Pediatric High-Grade Glioma (Supratentorial and Midline)

Status: draft · Last updated 2026-11-13 · By Jason S. Hauptman, MD, PhD (AI-assisted)

Read in the interactive book →

High-yield points

  • WHO 2021: pediatric HGG is not "pediatric GBM" .
    • Four pediatric-type entities:
    • DMG, H3 K27-altered: midline;
    • H3 G34-mutant: hemispheric;
    • H3/IDH-wildtype;
    • infant-type hemispheric: RTK fusions.
    • Grade III vs. IV ("anaplastic astrocytoma" vs. "GBM") doesn't predict survival in children .
  • Histone mutations :
    • Frequency: found in about a third of pediatric GBM.
    • Exclusivity: mutually exclusive with IDH.
    • Location: K27 is midline, and G34 is hemispheric.
  • Surgery:
    • GTR prolongs survival in hemispheric HGG (HR 0.29). STR is little better than biopsy.
    • Midline tumors: no proven resection benefit .
    • Always get tissue for molecular profiling.
  • Chemoradiation:
    • Temozolomide alone: 3-year EFS about 11% .
    • Adding lomustine: about 22% .
    • Bevacizumab: no benefit .
  • Targetable alterations:
    • BRAF V600: dabrafenib + trametinib, ORR 56%.
    • NTRK: larotrectinib.
    • ALK/ROS1/MET in infants.
    • H3 K27M: ONC201, FDA-approved 2025.
    • MMRD: checkpoint inhibitors .
  • Infant HGG has a paradoxically better prognosis, especially when fusion-positive .

Landmark papers

  • HERBY (Grill et al., J Clin Oncol 2018): a randomized phase II trial of bevacizumab in pediatric high-grade glioma. Median EFS was 8.2 months with bevacizumab vs 11.8 months without (HR 1.44, P = .13) .
  • Extent of resection (Hatoum et al., JAMA Netw Open 2022): a meta-analysis of 37 studies (1,387 patients). GTR vs STR carried a risk of death of RR 0.69 at 1 year and RR 0.74 at 2 years .

Pediatric high-grade gliomas (pHGG) are biologically distinct from adult glioblastoma. They are driven by histone H3 mutations and by other alterations, rarely by IDH. The 2021 WHO classification therefore groups them as "pediatric-type diffuse high-grade gliomas" . Under it:

Location, age and molecular class predict behavior better than histologic grade does.

Jason S. Hauptman, MD, PhD© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure from Hauptman's High Yield Thoughts in Pediatric Neurosurgery (pedsneurosurg.org). Do not copy, reproduce, redistribute or adapt without written permission.https://www.pedsneurosurg.org/hy-peds-ns:hgg_pediatric:b7ba14a9935b28ef© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure; please do not copy, reproduce or redistribute without written permission.Pediatric-type diffuse high-grade gliomas by site: diffuse midline glioma, H3 K27-altered, infiltrating the thalamus, pons and upper cervical cord; and in the hemispheres, diffuse hemispheric glioma H3 G34-mutant, diffuse pediatric-type high-grade glioma H3-wildtype and IDH-wildtype, and infant-type hemispheric glioma(A) MIDLINE (MIDSAGITTAL, ANTERIOR LEFT)Diffuse midline glioma,H3 K27-alteredone family; infiltrativethalamusponsupper cervical cord(B) HEMISPHERIC (LATERAL VIEW, ANTERIOR LEFT)Diffuse hemispheric glioma,H3 G34-mutantadolescents / young adultsDiffuse pediatric-type HGG,H3-wildtype and IDH-wildtypehemisphericInfant-type hemispheric gliomalarge, well demarcatedinfants; NTRK/ALK/ROS1/MET fusionsWHO 2021 pediatric-type diffuse high-grade gliomas; schematic, not to scale
Where the WHO 2021 pediatric-type diffuse high-grade gliomas arise. Diffuse midline glioma, H3 K27-altered, infiltrates the thalamus, pons and spinal cord. Diffuse hemispheric glioma, H3 G34-mutant, arises in the cerebral hemispheres of adolescents and young adults. Diffuse pediatric-type HGG, H3-wildtype and IDH-wildtype, is mostly hemispheric. Infant-type hemispheric glioma is a large hemispheric mass in infants, driven by NTRK, ALK, ROS1 or MET fusions. Not to scale.

WHO 2021 types and their biology

1. Diffuse midline glioma (DMG), H3 K27-altered: - Where: thalamus, brainstem (pons) and spinal cord. - Molecular: H3 K27M or, alternatively, EZHIP overexpression; hence "altered," not "mutant." Partners include TP53, ACVR1, PDGFRA and EGFR. - Grade: 4. 2. Diffuse hemispheric glioma, H3 G34-mutant: - Where: the cerebral hemispheres. - Molecular: G34R/V with TP53 and ATRX. - Grade: 4. 3. Diffuse pediatric-type HGG, H3-wildtype and IDH-wildtype: - Molecular: defined by PDGFRA, MYCN or EGFR alterations and the methylome. 4. Infant-type hemispheric glioma: - Who: newborns and infants. - Molecular: receptor tyrosine kinase fusions (NTRK family, ALK, ROS1, MET).

Special groups

Surgery

Adjuvant therapy

Targeted therapy

Related topics

References

  1. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23(8):1231–1251. doi:10.1093/neuonc/noab106. PMID 34185076. verified
  2. Varlet P, Le Teuff G, Le Deley MC, et al. WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial. Neuro Oncol 2020;22(1):116–127. doi:10.1093/neuonc/noz142. PMID 31419298. verified
  3. Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012;482(7384):226–231. doi:10.1038/nature10833. PMID 22286061. verified
  4. Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012;22(4):425–437. doi:10.1016/j.ccr.2012.08.024. PMID 23079654. verified
  5. Mackay A, Burford A, Carvalho D, et al. Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell 2017;32(4):520–537.e5. doi:10.1016/j.ccell.2017.08.017. PMID 28966033. verified
  6. Guerreiro Stucklin AS, Ryall S, Fukuoka K, et al. Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. Nat Commun 2019;10(1):4343. doi:10.1038/s41467-019-12187-5. PMID 31554817. verified
  7. Clarke M, Mackay A, Ismer B, et al. Infant high-grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes. Cancer Discov 2020;10(7):942–963. doi:10.1158/2159-8290.CD-19-1030. PMID 32238360. verified
  8. Wang L, Li Z, Zhang M, et al. H3 K27M-mutant diffuse midline gliomas in different anatomical locations. Hum Pathol 2018;78:89–96. doi:10.1016/j.humpath.2018.04.015. PMID 29727696. verified
  9. Bouffet E, Larouche V, Campbell BB, et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 2016;34(19):2206–2211. doi:10.1200/JCO.2016.66.6552. PMID 27001570. verified
  10. Hatoum R, Chen JS, Lavergne P, et al. Extent of tumor resection and survival in pediatric patients with high-grade gliomas: a systematic review and meta-analysis. JAMA Netw Open 2022;5(8):e2226551. doi:10.1001/jamanetworkopen.2022.26551. PMID 35972743. verified
  11. Hargrave DR, Terashima K, Hara J, et al. Phase II trial of dabrafenib plus trametinib in relapsed/refractory BRAF V600-mutant pediatric high-grade glioma. J Clin Oncol 2023;41(33):5174–5183. doi:10.1200/JCO.23.00558. PMID 37643378. verified
  12. Doz F, van Tilburg CM, Geoerger B, et al. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro Oncol 2022;24(6):997–1007. doi:10.1093/neuonc/noab274. PMID 34850167. verified
  13. Cohen KJ, Pollack IF, Zhou T, et al. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol 2011;13(3):317–323. doi:10.1093/neuonc/noq191. PMID 21339192. verified
  14. Jakacki RI, Cohen KJ, Buxton A, et al. Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study. Neuro Oncol 2016;18(10):1442–1450. doi:10.1093/neuonc/now038. PMID 27006176. verified
  15. Grill J, Massimino M, Bouffet E, et al. Phase II, open-label, randomized, multicenter trial (HERBY) of bevacizumab in pediatric patients with newly diagnosed high-grade glioma. J Clin Oncol 2018;36(10):951–958. doi:10.1200/JCO.2017.76.0611. PMID 29412784. verified
  16. Arrillaga-Romany I, Gardner SL, Odia Y, et al. ONC201 (dordaviprone) in recurrent H3 K27M-mutant diffuse midline glioma. J Clin Oncol 2024;42(13):1542–1552. doi:10.1200/JCO.23.01134. PMID 38335473. verified
  17. Blair HA. Dordaviprone: first approval. Drugs 2026;86(1):101–109. doi:10.1007/s40265-025-02252-3. PMID 41138047. verified

Verification (2026-11-13): each reference's authors, title, journal, volume, pages, DOI and PMID were checked on PubMed. Numbers were checked against the PubMed abstracts. The WHO 2021 type definitions (locations and genes) come from the full text of reference 1, since its abstract does not list them.

Caveats: